Clinical trial
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial…
NCT00417170 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00417170 |
|---|---|
| Title | Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome |
| Official title | A Double-blind, Double Dummy, Randomized Parallel Design Trial to Study the Effects of 12 Weeks of Treatment With 300mg Aliskiren vs. 5mg Amlodipine on Insulin Resistance and Endothelial Dysfunction in Hypertensive Patients With Metabolic Syndrome |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction |
| Intervention type | Drug |
| Interventions | Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine |
| Enrollment | 48 |
| Start date | Oct 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Dec 29, 2006 |
| Last update posted | Sep 26, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: